Evidence map›Paper›PMID 40374850›Full record

Articlenpj antimicrobials and resistance2025

A three-dimensional high throughput assay identifies novel antibacterial molecules with activity against intracellular Shigella.

Voong Vinh Phat, Andrew Shih Teong Lim, Cristina De Cozar-Gallardo, Maria Isabel Castellote Alvaro, Demetrio Muñoz Alvarez, Elena Fernandez Alvaro, Lluis Ballell-Pages, Sonia Lozano-Arias, Stephen Baker

Abstract read
In one paragraph

Article in npj antimicrobials and resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Multidrug-ResistantPolish journal of microbiology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Voong Vinh Phat *The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Andrew Shih Teong Lim *The ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge, United Kingdom.
Cristina De Cozar-GallardoGSK Global Health, Tres Cantos, Madrid, Spain.
Maria Isabel Castellote AlvaroMolecular Modalities Discovery, GSK, Tres Cantos, Madrid, Spain.
Demetrio Muñoz AlvarezGSK Global Health, Tres Cantos, Madrid, Spain.
Elena Fernandez AlvaroGSK Global Health, Tres Cantos, Madrid, Spain.
Lluis Ballell-PagesGSK Global Health, Tres Cantos, Madrid, Spain.
Sonia Lozano-Arias *GSK Global Health, Tres Cantos, Madrid, Spain. sonia.a.lozano@gsk.com.
Stephen BakerA*STAR Infectious Diseases Labs (A*STAR IDL), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore. stephenb@idlabs.a-star.edu.sg.

Funding

Tres Cantos Open Lab Foundation TC239Wellcome TrustWellcome Trust 215515/Z/19/Z
6 · The paper itself

Abstract

The Gram-negative bacterial species Shigella is the second leading cause of diarrhea among children in low and middle-income countries (LMICs) and is a World Health Organization (WHO) priority pathogen. Shigella infections are becoming increasing difficult to treat due to antimicrobial resistance (AMR), leading to an urgent need for new antimicrobial agents with novel modes of action. Shigella pathogenesis is largely intracellular and antibacterial chemicals that preferentially work inside cells may be desirable to limit collateral AMR and block key components of the Shigella infection cycle. Aiming to facilitate the process of identifying antibacterial chemicals that kill intracellular Shigella, we developed a high-throughput screening (HTS) cell-based chemical screening assay. The three-dimensional (3-D) assay, incorporating Shigella invasion into Caco-2 cells on Cytodex 3 beads, was scaled into a 384-well platform for screening chemical compound libraries. Using this assay, we evaluated >500,000 compounds, identifying 12 chemical hits that inhibit Shigella replication inside cells. This simple, efficient and HTS-compatible assays circumvents many of the limitations of traditional screening methods with cell monolayers and may be deployed for antibacterial compound screening for other intracellular pathogens.

Identifiers

PMID40374850
PMCPMC12081684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.